PE20120923A1 - Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo - Google Patents
Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismoInfo
- Publication number
- PE20120923A1 PE20120923A1 PE2011001735A PE2011001735A PE20120923A1 PE 20120923 A1 PE20120923 A1 PE 20120923A1 PE 2011001735 A PE2011001735 A PE 2011001735A PE 2011001735 A PE2011001735 A PE 2011001735A PE 20120923 A1 PE20120923 A1 PE 20120923A1
- Authority
- PE
- Peru
- Prior art keywords
- concentration
- salt
- pharmaceutical compositions
- compositions including
- liposomes containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIPOSOMAS QUE CONTIENE: A) UNA FASE INTERNA QUE COMPRENDE i) UN COMPUESTO ACTIVO TAL COMO MESILATO DE ERIBULINA EN UNA CONCENTRACION DE 0.01 A 300 MG/ML; ii) UNA SAL DE AMONIO TAL COMO SULFATO DE AMONIO, UN ACIDO TAL COMO ACIDO CITRICO, UNA BASE Y UN AMINOACIDO EN UNA CONCENTRACION DE 1 A 300 mM CADA UNO; B) UNA FASE EXTERNA QUE COMPRENDE i) UN AZUCAR TAL COMO SACAROSA EN UNA CONCENTRACION DE 2 A 20%; ii) UN ELECTROLITO TAL COMO CLORURO DE SODIO; iii) UN AMINOACIDO TAL COMO HISTIDINA EN UNA CONCENTRACION DE 1 A 300 mM; C) FOSFATIDILCOLINA HIDROGENADA EN UNA CANTIDAD DE 10 A 80%; D) COLESTEROL EN UNA CANTIDAD DE 1 A 60%; Y E) UN CONDENSADO DE DIESTEAROILFOSFATIDIL ETANOLAMINO POLIETILENGLICOL EN UNA CANTIDAD DE HASTA 50%. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE MELANOMA, FIBROSARCOMA, LEUCEMIA MONOCITICA, CANCER DE COLON
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16465309P | 2009-03-30 | 2009-03-30 | |
| JP2009082521 | 2009-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120923A1 true PE20120923A1 (es) | 2012-08-27 |
Family
ID=42828273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001798A PE20151519A1 (es) | 2009-03-30 | 2010-03-30 | Composicion de liposoma |
| PE2011001735A PE20120923A1 (es) | 2009-03-30 | 2010-03-30 | Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001798A PE20151519A1 (es) | 2009-03-30 | 2010-03-30 | Composicion de liposoma |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US20120058178A1 (es) |
| EP (1) | EP2415470B1 (es) |
| JP (1) | JP5551683B2 (es) |
| KR (1) | KR101495951B1 (es) |
| CN (1) | CN102369008B (es) |
| AU (1) | AU2010232347A1 (es) |
| BR (1) | BRPI1014527B8 (es) |
| CA (1) | CA2756811C (es) |
| CO (1) | CO6430500A2 (es) |
| CY (1) | CY1118231T1 (es) |
| DK (1) | DK2415470T3 (es) |
| ES (1) | ES2593027T3 (es) |
| HK (1) | HK1165707A1 (es) |
| HR (1) | HRP20161157T1 (es) |
| HU (1) | HUE029577T2 (es) |
| IL (1) | IL215059A (es) |
| LT (1) | LT2415470T (es) |
| MA (1) | MA33127B1 (es) |
| ME (1) | ME02518B (es) |
| MX (1) | MX2011009632A (es) |
| MY (1) | MY160203A (es) |
| NZ (1) | NZ595212A (es) |
| PE (2) | PE20151519A1 (es) |
| PL (1) | PL2415470T3 (es) |
| PT (1) | PT2415470T (es) |
| RS (1) | RS55148B1 (es) |
| SG (1) | SG174255A1 (es) |
| SI (1) | SI2415470T1 (es) |
| SM (1) | SMT201600307B (es) |
| TW (1) | TWI392519B (es) |
| UA (1) | UA103794C2 (es) |
| WO (1) | WO2010113984A1 (es) |
| ZA (1) | ZA201106535B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| CN101209243B (zh) | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术（石家庄）有限公司 | 一种脂质体药物及其制备方法 |
| US20120058178A1 (en) | 2009-03-30 | 2012-03-08 | Eisai R&D Management Co., Ltd. | Liposome Composition |
| JP5622719B2 (ja) | 2009-03-30 | 2014-11-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
| RU2561582C2 (ru) * | 2010-11-19 | 2015-08-27 | Российская Федерация в лице Министерства промышленности и торговли Российской Федерации | Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения |
| WO2012119077A1 (en) | 2011-03-02 | 2012-09-07 | Morphotek Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| DK2950784T3 (da) * | 2013-02-01 | 2021-07-05 | Zoneone Pharma Inc | Fjernladning af svagt vandopløselige lægemidler i liposomer |
| WO2016022549A1 (en) | 2014-08-04 | 2016-02-11 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into lipid vesicles |
| CA2977397A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| CN108137694B (zh) | 2015-09-18 | 2022-08-12 | 慕尼黑工业大学 | 整合素αvβ6的配体及其合成和应用 |
| WO2017078009A1 (ja) * | 2015-11-02 | 2017-05-11 | 富士フイルム株式会社 | リポソーム組成物およびその製造方法 |
| ES2952680T3 (es) | 2016-04-28 | 2023-11-03 | Eisai R&D Man Co Ltd | Eribulina para inhibir el crecimiento tumoral |
| KR20190122676A (ko) * | 2017-01-18 | 2019-10-30 | 테마섹 라이프 사이언스 래보러토리 리미티드 | 유사분열기세포의 표적화를 증가시키는 고안정화된 리포좀 |
| US11332498B2 (en) | 2017-03-17 | 2022-05-17 | Technische Universitat Munchen | Ligands for integrin αVβ8, synthesis and uses thereof |
| RU2734900C1 (ru) * | 2017-03-31 | 2020-10-26 | Фуджифилм Корпорэйшн | Липосомальная композиция и фармацевтическая композиция |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| EP4159210A4 (en) * | 2020-05-29 | 2023-08-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | LIPOSOME CONTAINING ETHYLENEDIAMINE TETRAACETIC ACID OR A SALT THEREOF AND ERIBULIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| CN115957351B (zh) * | 2022-11-15 | 2023-06-27 | 中国人民解放军海军第九七一医院 | 一种碘海醇注射液及其制备方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
| JP3545403B2 (ja) | 1993-04-22 | 2004-07-21 | スカイファルマ インコーポレイテッド | 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法 |
| FR2736056B1 (fr) | 1995-06-29 | 1997-08-08 | Commissariat Energie Atomique | Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises |
| US6051251A (en) | 1997-11-20 | 2000-04-18 | Alza Corporation | Liposome loading method using a boronic acid compound |
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| WO1999065894A1 (en) | 1998-06-17 | 1999-12-23 | Eisai Co., Ltd. | Macrocyclic analogs and methods of their use and preparation |
| US6593308B2 (en) | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
| CN1116875C (zh) | 2000-10-19 | 2003-08-06 | 南京振中生物工程有限公司 | 紫杉醇脂质组合物及其制备方法 |
| EP1443900B1 (en) * | 2001-11-13 | 2012-05-23 | Celator Pharmaceuticals, Inc. | Lipid carrier compositions with enhanced blood stability |
| WO2003041682A2 (en) | 2001-11-13 | 2003-05-22 | Celator Technologies, Inc. | Lipid carrier compositions and methods for improved drug retention |
| DE10255106A1 (de) | 2002-11-24 | 2004-06-09 | Novosom Ag | Liposomale Glucocorticoide |
| EP1565165A2 (en) | 2002-11-26 | 2005-08-24 | Gilead Sciences, Inc. | Liposomal formulations |
| NZ540778A (en) * | 2002-12-31 | 2008-04-30 | Zydus Bsv Res And Dev Private | Non-pegylated long-circulating liposomes |
| CA2528001A1 (en) * | 2003-04-04 | 2004-10-21 | The University Of Tokyo | Lipid membrane structure containing anti-mt-mmp monoclonal antibody |
| US6747011B1 (en) | 2003-06-04 | 2004-06-08 | A.P. Group, Inc. | Antitumor drugs and methods |
| US20050129753A1 (en) | 2003-11-14 | 2005-06-16 | Gabizon Alberto A. | Method for drug loading in liposomes |
| CN101497595A (zh) | 2004-01-29 | 2009-08-05 | 卫材R&D管理有限公司 | 大环内酯类化合物的稳定化方法 |
| EP1746976B1 (en) * | 2004-05-03 | 2017-01-11 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery |
| EP1750673B1 (en) | 2004-05-17 | 2009-12-02 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
| KR101434673B1 (ko) | 2004-06-03 | 2014-08-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 ｂ 유사체의 제조를 위한 중간체 |
| WO2006037230A1 (en) | 2004-10-06 | 2006-04-13 | Bc Cancer Agency | Liposomes with improved drug retention for treatment of cancer |
| TWI373473B (en) | 2005-09-02 | 2012-10-01 | Otsuka Pharma Co Ltd | Anticancer agent |
| CN101209243B (zh) * | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术（石家庄）有限公司 | 一种脂质体药物及其制备方法 |
| US20090196913A1 (en) | 2007-05-11 | 2009-08-06 | Ken Shi Kun Huang | Anti-Alpha-V Immunoliposome Composition, Methods, and Uses |
| US20090196917A1 (en) | 2008-02-01 | 2009-08-06 | University Of Kentucky Research Foundation | Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions |
| JP5622719B2 (ja) | 2009-03-30 | 2014-11-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
| US20120058178A1 (en) | 2009-03-30 | 2012-03-08 | Eisai R&D Management Co., Ltd. | Liposome Composition |
| MX2012008510A (es) | 2010-01-26 | 2012-11-21 | Eisai R&D Man Co Ltd | Derivados de furo [3, 2-b] pirano utiles en la sintesis de analogos de halicondrina b. |
| WO2012139039A2 (en) | 2011-04-08 | 2012-10-11 | British Columbia Cancer Agency Branch | Bisphenol compounds and methods for their use |
| AU2012284147A1 (en) | 2011-07-19 | 2014-02-27 | Stc. Unm | Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers |
| CN105338977B (zh) | 2013-06-26 | 2018-10-16 | 卫材R&D管理有限公司 | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 |
| US9855217B2 (en) | 2013-09-18 | 2018-01-02 | Stc. Unm | Toroidal mesoporous silica nanoparticles (TMSNPs) and related protocells |
| WO2015095784A1 (en) | 2013-12-19 | 2015-06-25 | Luminus Biosciences, Inc. | Solid nanoparticle formulation of microtubule inhibitors with reduced ostwald ripening for oral administration |
| EP3113775A4 (en) | 2014-03-03 | 2017-08-23 | Eisai R&D Management Co., Ltd. | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
| US10238630B2 (en) | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| CN105640935A (zh) | 2014-11-12 | 2016-06-08 | 天津市汉康医药生物技术有限公司 | 供注射用甲磺酸艾日布林药物组合物 |
-
2010
- 2010-03-30 US US13/260,872 patent/US20120058178A1/en not_active Abandoned
- 2010-03-30 PE PE2015001798A patent/PE20151519A1/es unknown
- 2010-03-30 DK DK10758755.2T patent/DK2415470T3/en active
- 2010-03-30 MX MX2011009632A patent/MX2011009632A/es active IP Right Grant
- 2010-03-30 ME MEP-2016-188A patent/ME02518B/me unknown
- 2010-03-30 EP EP10758755.2A patent/EP2415470B1/en active Active
- 2010-03-30 MY MYPI2011004382A patent/MY160203A/en unknown
- 2010-03-30 SI SI201031275A patent/SI2415470T1/sl unknown
- 2010-03-30 TW TW099109838A patent/TWI392519B/zh active
- 2010-03-30 PE PE2011001735A patent/PE20120923A1/es not_active Application Discontinuation
- 2010-03-30 ES ES10758755.2T patent/ES2593027T3/es active Active
- 2010-03-30 PL PL10758755.2T patent/PL2415470T3/pl unknown
- 2010-03-30 NZ NZ595212A patent/NZ595212A/en unknown
- 2010-03-30 JP JP2011507240A patent/JP5551683B2/ja active Active
- 2010-03-30 AU AU2010232347A patent/AU2010232347A1/en not_active Abandoned
- 2010-03-30 RS RS20160763A patent/RS55148B1/sr unknown
- 2010-03-30 CN CN201080014698.2A patent/CN102369008B/zh active Active
- 2010-03-30 BR BRPI1014527A patent/BRPI1014527B8/pt active IP Right Grant
- 2010-03-30 SG SG2011063880A patent/SG174255A1/en unknown
- 2010-03-30 CA CA2756811A patent/CA2756811C/en active Active
- 2010-03-30 LT LTEP10758755.2T patent/LT2415470T/lt unknown
- 2010-03-30 UA UAA201111426A patent/UA103794C2/ru unknown
- 2010-03-30 HU HUE10758755A patent/HUE029577T2/en unknown
- 2010-03-30 MA MA34174A patent/MA33127B1/fr unknown
- 2010-03-30 PT PT107587552T patent/PT2415470T/pt unknown
- 2010-03-30 KR KR1020117022860A patent/KR101495951B1/ko active IP Right Grant
- 2010-03-30 WO PCT/JP2010/055770 patent/WO2010113984A1/ja active Application Filing
-
2011
- 2011-09-07 ZA ZA2011/06535A patent/ZA201106535B/en unknown
- 2011-09-08 IL IL215059A patent/IL215059A/en active IP Right Grant
- 2011-10-04 CO CO11130828A patent/CO6430500A2/es active IP Right Grant
-
2012
- 2012-06-29 HK HK12106366.9A patent/HK1165707A1/zh unknown
-
2013
- 2013-10-23 US US14/061,426 patent/US20140044777A1/en active Pending
-
2016
- 2016-09-08 SM SM201600307T patent/SMT201600307B/it unknown
- 2016-09-08 HR HRP20161157TT patent/HRP20161157T1/hr unknown
- 2016-09-14 CY CY20161100911T patent/CY1118231T1/el unknown
-
2020
- 2020-10-09 US US17/067,302 patent/US11071713B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120923A1 (es) | Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo | |
| MX2015011955A (es) | Lipidos y composiciones de lipidos para el suministro de agentes activos. | |
| EA026385B9 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
| EA201201161A1 (ru) | Пирролопиримидины в качестве ингибиторов cdk4/6 | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| MD20130095A2 (en) | Fused benzoxazepinones as ion channel modulators | |
| EA201001368A1 (ru) | Гетероциклические производные мочевины и способы их применения-211 | |
| EA201071094A1 (ru) | Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| MX2010010647A (es) | Proceso para preparar formulaciones de dabigatran para administracion oral. | |
| EA201101671A1 (ru) | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина | |
| MX2013014843A (es) | Oxazepinas como moduladores del canal de iones. | |
| EA201390934A1 (ru) | Композиции и способы модулирования fxr | |
| EA201200939A1 (ru) | Липиды, липидные композиции и способы их применения | |
| MX2011012627A (es) | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. | |
| MX361350B (es) | Compuestos heterocíclicos fusionados como moduladores del canal de sodio. | |
| EA200870448A1 (ru) | Тризамещенные 1,2,4-триазолы | |
| EA201400311A1 (ru) | Аминозамещенные имидазопиридазины | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| MX2009004475A (es) | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. | |
| TW200639159A (en) | Treatment of pain | |
| TN2012000371A1 (en) | Pyrazole compounds as crth2 antagonists | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| EA201391555A1 (ru) | Составы суспензионного типа для местного применения, содержащие циклический депсипептид | |
| PE20120788A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos | |
| EA201001858A1 (ru) | Гетероциклические производные мочевины для лечения бактериальных инфекций |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |